Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity (Q44785944)

From Wikidata

Jump to navigation Jump to search

scientific article published on 27 November 2006

Language	Label	Description	Also known as
English	Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity	scientific article published on 27 November 2006

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

1 reference

based on heuristic

inferred from title

object named as

vaccinia virus

1 reference

based on heuristic

inferred from title

object named as

Eftyhia Vardas

3

0 references

Giuseppe Pantaleo

22

object named as

Giuseppe Pantaleo

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

2

object named as

Walter Jaoko

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Andrew James McMichael

20

object named as

Andrew J McMichael

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Linda Sylvia Klavinskis

11

object named as

Linda Klavinskis

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

author name string

Barry S Peters

1

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

George Panayotakopoulos

4

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Patricia Fast

5

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Claudia Schmidt

6

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Jill Gilmour

7

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Mampedi Bogoshi

8

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Gloria Omosa-Manyonyi

9

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Len Dally

10

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Bashir Farah

12

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Tony Tarragona

13

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Pierre-Alexandre Bart

14

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Andrew Robinson

15

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Colleen Pieterse

16

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Wendy Stevens

17

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Richard Thomas

18

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Burc Barin

19

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

James A McIntyre

21

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Tomás Hanke

23

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Job Bwayo

24

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

language of work or name

0 references

publication date

27 November 2006

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

25

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

2120-2127

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.016

7 January 2021

Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.016

7 January 2021

A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.016

7 January 2021

Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-1MN env gene

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.016

7 January 2021

Vaccination of seronegative volunteers with a human immunodeficiency virus type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of beta-chemokines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.016

7 January 2021

HIV vaccine fails in phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.016

7 January 2021

Recombinant modified vaccinia virus Ankara-simian immunodeficiency virus gag pol elicits cytotoxic T lymphocytes in rhesus monkeys detected by a major histocompatibility complex class I/peptide tetramer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.016

7 January 2021

Engineering RENTA, a DNA prime-MVA boost HIV vaccine tailored for Eastern and Central Africa

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.016

7 January 2021

Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.016

7 January 2021

Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.016

7 January 2021

Multiprotein HIV type 1 clade B DNA/MVA vaccine: construction, safety, and immunogenicity in Macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.016

7 January 2021

Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.016

7 January 2021

A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.016

7 January 2021

Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.016

7 January 2021

Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.016

7 January 2021

Immunogenicities of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.016

7 January 2021

Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag c

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.016

7 January 2021

Safety profile of recombinant canarypox HIV vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.016

7 January 2021

Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.016

7 January 2021

Expansion and diversification of virus-specific T cells following immunization of human immunodeficiency virus type 1 (HIV-1)-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 Gag vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.016

7 January 2021

Therapeutic immunization of highly active antiretroviral therapy-treated HIV-1-infected patients: safety and immunogenicity of an HIV-1 gag/poly-epitope DNA vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.016

7 January 2021

AIDS vaccine models: challenging challenge viruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.016

7 January 2021

HIV vaccines: new frontiers in vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.016

7 January 2021

Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.11.016

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2006.11.016

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44785944&oldid=2041138228"